Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Phosphorus containing other than solely as part of an...
Reexamination Certificate
2011-03-08
2011-03-08
Shiao, Rei-tsang (Department: 1628)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Phosphorus containing other than solely as part of an...
C558S169000, C558S170000, C558S172000
Reexamination Certificate
active
07902176
ABSTRACT:
Novel synthetic oxidized lipids and methods utilizing oxidized lipids for treating and preventing an inflammation associated with an endogenous oxidized lipid are provided.
REFERENCES:
patent: 4329302 (1982-05-01), Hanahan et al.
patent: 4410237 (1983-10-01), Veldkamp
patent: 4614796 (1986-09-01), Kawamata et al.
patent: 4711512 (1987-12-01), Upatnieks
patent: 4827011 (1989-05-01), Wissner et al.
patent: 5061626 (1991-10-01), Baldo et al.
patent: 5082629 (1992-01-01), Burgess, Jr. et al.
patent: 5091527 (1992-02-01), Junius et al.
patent: 5224198 (1993-06-01), Jachimowicz et al.
patent: 5237451 (1993-08-01), Saxe
patent: 5660855 (1997-08-01), Male-Brune
patent: 5742262 (1998-04-01), Tabata et al.
patent: 5747340 (1998-05-01), Harats et al.
patent: 5761177 (1998-06-01), Muneyoshi et al.
patent: 5835661 (1998-11-01), Tai et al.
patent: 5962437 (1999-10-01), Kucera et al.
patent: 6580529 (2003-06-01), Amitai et al.
patent: 6611385 (2003-08-01), Song
patent: 6805490 (2004-10-01), Levola
patent: 6822770 (2004-11-01), Takeyama
patent: 6833955 (2004-12-01), Niv
patent: 6838452 (2005-01-01), Harats et al.
patent: 7206107 (2007-04-01), Levola
patent: 2002/0102241 (2002-08-01), Arnaout et al.
patent: 2002/0158131 (2002-10-01), Dickson et al.
patent: 2003/0040509 (2003-02-01), Moskowitz
patent: 2003/0067685 (2003-04-01), Niv
patent: 2003/0202247 (2003-10-01), Niv et al.
patent: 2003/0225035 (2003-12-01), Harats et al.
patent: 2004/0051957 (2004-03-01), Liang
patent: 2004/0106677 (2004-06-01), Harats et al.
patent: 2005/0026023 (2005-02-01), Hirai et al.
patent: 2005/0201693 (2005-09-01), Korenaga et al.
patent: 2005/0272813 (2005-12-01), Harats et al.
patent: 2006/0056028 (2006-03-01), Wildnauer
patent: 2006/0126179 (2006-06-01), Levola
patent: 2006/0194765 (2006-08-01), Garcia et al.
patent: 2007/0065942 (2007-03-01), Wandinger-Ness et al.
patent: 2007/0099868 (2007-05-01), Harats et al.
patent: 2009/0209775 (2009-08-01), Harats et al.
patent: 2010/0048515 (2010-02-01), Harats et al.
patent: 642665 (1984-04-01), None
patent: 0121088 (1984-10-01), None
patent: 0142333 (1985-05-01), None
patent: 2019552 (1991-06-01), None
patent: 331167 (1992-07-01), None
patent: 1031870 (2000-08-01), None
patent: 1333308 (2003-08-01), None
patent: 1577872 (2005-09-01), None
patent: 2019552 (1991-06-01), None
patent: 60-104066 (1985-06-01), None
patent: 63-135395 (1988-06-01), None
patent: 63054386 (1988-08-01), None
patent: 01-258691 (1989-10-01), None
patent: 04-097201 (1992-03-01), None
patent: 06-230225 (1994-08-01), None
patent: 06-250022 (1994-09-01), None
patent: 07-258261 (1995-10-01), None
patent: WO 87/05904 (1987-10-01), None
patent: WO 95/11473 (1995-04-01), None
patent: WO 95/23592 (1995-08-01), None
patent: WO 02/41827 (2002-05-01), None
patent: WO 03/032017 (2003-04-01), None
patent: WO 03/091763 (2003-11-01), None
patent: WO 2005/021738 (2005-03-01), None
patent: WO 2007/031991 (2007-03-01), None
patent: WO 2007/031992 (2007-03-01), None
patent: WO 2007/052265 (2007-05-01), None
patent: WO 2007/138576 (2007-12-01), None
patent: WO 2008/020450 (2008-02-01), None
patent: WO 2008/132729 (2008-11-01), None
Communication Pursuant to Article 94(3) EPC Dated Nov. 9, 2009 From the European Patent Office Re.: Application No. 01997274.4.
Examiner's Report DatedSep. 2, 2009 From the Australian Government, IP Australia Re.: Application No. 2004243695.
Supplementary European Search Report Dated Aug. 3, 2009 From the European Patent Office Re.: Application No. 01997274.4.
Deigner et al. “Effect of Platelet Activating Factor on the Kinetics of LDL Oxidation In Vitro”, FEBS Letters, XP025615837, 317(3): 202-206, Feb. 15, 1993. Abstract, p. 205-206.
Itabe et al. “Oxidized Phosphatidylcholines That Modify Proteins. Analysis by Monoclonal Antibody Against Oxidized Low Density”, The Journal of Biological Chemistry, XP002532604, 271(52): 33208-33217, Dec. 27, 1996. Abstract, p. 33216.
Itabe et al. “Preparation of Radioactive Aldehyde-Containing Phosphatidylcholine”, Analytical Biochemistry, XP002532603, 285(1): 151-155, Oct. 1, 2000. Abstract, p. 152.
Watson et al. “Structural Identification by Mass Spectrometry of Oxidized Phospholipids in Minimally Oxidized Low Density Lipoprotein That Induce Monocyte/Endothelial Interactions and Evidence for Their Presence In Vivo”, Journal of Biological Chemistry, 272(21): 13597-13607, 1997. Esp. p. 13603.
Shaw et al. “Natural Antibodies With the T15 Idiotype May Act in Atherosclerosis, Apoptotic Clearance, and Protective Immunity,” The Journal of Clinical Investigation, 105(12): 1731-1740, 2000. Abstract.
Subbanagounder et al. “Determinants of Bioactivity of Oxydized Phospholipids: Specific Oxidized Fatty Acyl Groups at the SN-2 Position,” Arteriosclerosis Thromb. Vasc. Biol., p. 2248-2254, 2000.
Boullier et al. “The Binding of Oxidized Low Density Lipoprotein to Mouse CD36 Is Mediated in Part by Oxidized Phospholipids That Are Associated With Both the Lipid and Protein Moieties of the Lipoprotein”, The Journal of Biological Chemistry, 275(13): 9163-9169, 2000. Esp. p. 9163, 9164.
Subbanagounder et al. “Evidence That Phospholipid Oxidation Products and/or Platelet-Activating Factor Play An Important Role in Early Atherogenesis: In Vitro and In Vivo Inhibitation by WEB 2086”, Circulation Research, p. 311-318, 1999. p. 311-313, 317.
Ota et al. “Complexes of ApoA-1 With Phosphatidylcholine Suppress Dysregulation of Arterial Tone by Oxidized LDL”, The American Journal of Physiology, 273(3 Pt.2): 1215-1222. 1997.
Tokumura et al. “Cardiovascular Effects of Lysophophatidic Acid and Its Structural Analogs in Rats”, the Journal of Pharmacology and Experimental Therapeutics, 219(1): 219-222, 1981.
Leitinger et al. “Structurally Similar Oxidized Phospholipids Differentially Regulate Endothelial Binding of Monocytes and Neutrophils”, Proc. Natl. Acad. Sci. USA, 96(21): 12010-12015, 1999.
Macpherson et al. “Production and Characterization of Antibodies to Platelet-Activating Factor”, Journal of Lipid Mediators, 5(1): 49-59,1992. Abstract.
Wang et al. “A Facile Synthesis of an Aldehydic Analog of Platelet Activating Factor and Its Use in the Production of Specific Antibodies”, Chemistry and Physics of Lipids, 55(3): 265-273, 1990. Abstract.
Karasawa et al. “Antibodies to Synthetic Platelet-Activating Factor (1-0-Alkyl-2-0-Acetyl-SN-Glycero-3-Phosphocholine) Analogs With Substituents at the SN-2 Position”, Journal of Biochemistry, 110(5): 683-687, 1991. Abstract.
Smal et al. “Production of Antibodies to Platelet Activating Factor”, Molecular Immunology, 26(8): 711-719, 1989.
Nitta et al. “Phospholipase A2 Activity of Fcγ2b Receptors of Thioglycollate-Elicited Murine Peritoneal Macropharges”, Journal of Leukocyte Biology, 36(4): 493-504, 1984. Abstract.
Berchthold et al. “Synthesis of Carboxyphospholipids”, Chemistry and Physics of Lipids, 28(1): 55-60, 1981. Abstract.
Cooney et al. “Combining Site Specificities of Rabbit Antibodies to Platelet-Activating Factor (PAF)”, Molecular Immunology, 27(5): 405-412, 1990. Abstract.
Kern et al. “Stimulation of Monocytes and Platelets by Short-Chain Phosphatidylcholines With and Without Terminal Carboxyl Group”, Biochimica et Biophysica Acta, 1394(1): 33-42, 1998. Abstract.
Examiner's Report Dated Aug. 15, 2005 From the Australian Government, IP Australia Re.: Application No. 2002218461.
Notice of Allowance Dated Nov. 3, 2008 From the US Patent and Trademark Office Re.: U.S. Appl. No. 11/183,884.
Office Action Dated May 1, 2008 From the Israeli Patent Office Re.: Application No. 172165.
Office Action Dated Aug. 12, 2008 From the Israeli Patent Office Re.: Application No. 172165.
Office Action Dated Jan. 14, 2008 From the Israeli Patent. Office Re.: Application No. 172165.
Office Action Dated Oct. 17, 2008 From the State Intellectual Property Office of the People's Republic of Chin
George Jacob
Halperin Gideon
Harats Dror
Kovalevski-Ishai Eti
Yacov Niva
Shiao Rei-tsang
Vascular Biogenics Ltd.
LandOfFree
Oxidized lipids and uses thereof in the treatment of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Oxidized lipids and uses thereof in the treatment of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Oxidized lipids and uses thereof in the treatment of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2690529